For NSCLC harboring EGFR driver mutation, the current standard of treatment in the first-line setting is EGFR tyrosine kinase inhibitor (TKI), either first-generation (gefitinib or erlotinib) or second-generation TKI (afatinib) [3,4,5,6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.